Drug Profile
FLX 925
Alternative Names: AMG 925; FLX925Latest Information Update: 01 Jul 2019
Price :
$50
*
At a glance
- Originator Amgen
- Developer RAPT Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (PO)
- 25 Sep 2017 FLX Bio terminates a phase I trial in Acute myeloid leukaemia (Second-line therapy or greater) in USA, as the dose escalation part completed (PO) (NCT02335814)
- 08 Apr 2015 Flexus Biosciences has been acquired by Bristol-Myers Squibb